Get the Daily Brief
Latest Biotech News
Sana and peers trim pipelines — clinical‑stage programs deprioritized
Multiple biotechs announced portfolio realignments that push clinical‑stage programs off the immediate roadmap while prioritizing earlier‑stage or preclinical candidates. Sana Biotechnology, along...
Eledon eyes Phase III after mixed Phase II kidney transplant readout
Eledon Pharmaceuticals reported that tegoprubart failed to meet superiority against tacrolimus on the primary endpoint in the Bestow Phase II kidney transplant trial but produced preservation of...
MIT LNP cuts effective mRNA dose by 100x in mice — delivery breakthrough
MIT researchers developed a new class of degradable cyclic amino ionizable lipids and screened formulations to identify AMG1541, an LNP that achieved equivalent immune responses to FDA‑approved...
Intellia patient dies — CRISPR ATTR trials paused
An elderly patient treated with Intellia Therapeutics’ in vivo CRISPR candidate nexiguran ziclumeran (nex‑z) died after developing severe liver injury, the company disclosed. Intellia halted...
FDA expands priority-review vouchers: six more drugs added
The U.S. Food and Drug Administration announced a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six drugs to the expedited‑review pilot designed to accelerate...
Pfizer tops Novo with $10B bid for Metsera
Pfizer has won a contested auction for Metsera, the obesity‑focused biotech, agreeing to acquire the company for roughly $10 billion, according to reports. The deal concludes a high‑stakes bidding...
MIT nanoparticle cuts influenza mRNA dose 100‑fold — Potency up
Researchers at MIT reported a new lipid nanoparticle (LNP) formulation that delivered an influenza mRNA vaccine at roughly 1/100th the dose of current FDA‑approved LNP materials while achieving...
PacBio’s Sequel II CNDx cleared in China — First clinical long‑read approval
PacBio announced that Berry Genomics received National Medical Products Administration (NMPA) Class III approval in China for the Sequel II CNDx system paired with Berry’s clinical thalassemia...
Qiagen to acquire Parse Biosciences for up to $280M — Single‑cell deal
Qiagen agreed to buy Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell sequencing provider into a larger molecular‑diagnostics and sample‑processing portfolio....
Arima’s Hi‑C lymphoma assay aims to supplant FISH — FFPE‑compatible genomic mapping
Arima Genomics is advancing its Hi‑C‑based Aventa Lymphoma assay as an alternative to fluorescence in situ hybridization (FISH) for lymphoma diagnostics. The company published results showing Hi‑C...
Swiss Rockets secures CoolMPS license from MGI — Plans western NGS launch
Swiss Rockets obtained an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry for global commercialization outside the Asia‑Pacific region and announced plans to launch...
CMS unveils Generous model: Medicaid drug prices tied to international benchmarks
The Centers for Medicare & Medicaid Services’ Innovation Center launched the Generating Cost Reductions for U.S. Medicaid (GENEROUS) model, a voluntary five‑year pilot that will negotiate...
SGLT2 inhibitors cut kidney risk across eGFR and albuminuria levels — JAMA analysis
A landmark analysis presented in JAMA and at ASN Kidney Week assessed the benefits of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors across patients with varying baseline glomerular filtration...
Pfizer wins Metsera... Novo ups the ante
Pfizer closed a winning bid for obesity biotech Metsera after a late-stage bidding contest with Novo Nordisk, putting roughly $10 billion on the table. Metsera accepted Pfizer’s increased offer,...
Intellia CRISPR trial halted after patient dies — liver signal under scrutiny
Intellia Therapeutics disclosed the death of an elderly patient in its Phase III MAGNITUDE trial of nexiguran ziclumeran (nex‑z), an in vivo CRISPR base‑editing therapy for transthyretin...
FDA expands national‑priority voucher awards — more drugs fast‑tracked
The FDA issued a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six more therapies to a pilot program designed to accelerate review of drugs deemed in the national...
CMS launches 'GENERous' Medicaid drug model — prices tied to international benchmarks
The Centers for Medicare & Medicaid Services announced a five‑year voluntary model to lower Medicaid drug spending by negotiating prices tied to select international data. Under the Generating...
MIT LNP cuts mRNA dose 100‑fold — Nature Nanotech data
MIT researchers published a Nature Nanotechnology paper describing a new degradable cyclic amino ionizable lipid and LNP formulation that delivered an influenza mRNA vaccine at approximately...
China clears clinical long‑read sequencer; Swiss Rockets licenses CoolMPS
Berry Genomics received National Medical Products Administration Class III approval for PacBio’s Sequel II CNDx system — the first regulatory clearance for a clinical‑grade long‑read sequencer in...
SGLT2 class shows kidney benefits across populations — large analyses
A landmark nephrology analysis reinforced that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors deliver kidney and cardiovascular benefits across patients with differing glomerular filtration...